Europe Multiple Sclerosis Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Nov 2020
  • Europe
  • 350 Pages
  • No of Tables: 414
  • No of Figures: 45

Europe Multiple Sclerosis Treatment Market, By Disease Type (Relapsing–Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing–Remitting Multiple Sclerosis (RES)), Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies), Drug Type (Branded, Generic), Route of Administration (Oral, Parenteral), End User (Hospital, Homecare, Specialty Centers, Others), Distribution Channel (Retail Sales, Direct Tender), Country (U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and Rest of Europe) Industry Trends and Forecast to 2027

Europe Multiple Sclerosis Treatment Market Market Analysis and Insights: Europe Multiple Sclerosis Treatment Market

The multiple sclerosis treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.3% in the forecast period of 2020 to 2027 and is expected to reach USD 8,374.10 million by 2027. Rising awareness towards early disease diagnosis and technological advancement in multiple sclerosis treatment are the major drivers which propelled the demand of the multiple sclerosis treatment market in the forecast period.

Multiple sclerosis is a chronic, inflammatory, autoimmune disorder that affects the (CNS) central nervous system, especially the communication between the brain and other areas of the body. Multiple sclerosis (MS) in particular is a demyelinating disease that damages the insulating covers of nerve cells in the brain and spinal cord. There is usually no cure for MS, general care is based on speedy recovery from damage that delays disease progression and manages MS symptoms.

MS symptoms differ greatly and depend on the amount of damage to the nerves and the form and position of affected nerves. MS symptoms include numbness or weakness of limbs usually affecting one side of the body, partial or total loss of vision, double vision and feelings of electrical shock in some neck movements, tremor and lack of balance or erratic gait, slurred voice, nausea, dizziness, bowel and bladder issues among others. Extreme MS can affect walking ability independently or lead to total disability. The key causes of MS are problems with walking and balance, muscle weakness, fatigue, issues with vision but the symptoms of MS vary from patient to patient.

The rising number of patients, increased screening and the need for better care options are thought to be the key factors for the multiple sclerosis treatment market growth during the forecast period. In ageing population, the disease is more prone, hence the surge in the geriatric population further escalates the multiple sclerosis treatment market growth.

The multiple sclerosis treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the multiple sclerosis treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Multiple Sclerosis Treatment Market Multiple Sclerosis Treatment Market Scope and Market Size

The multiple sclerosis treatment market is segmented on the basis of disease type, treatment, drug type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the multiple sclerosis treatment market is segmented into relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS) and severe relapsing–remitting multiple sclerosis (RES). In 2020, relapsing–remitting multiple sclerosis (RRMS) segment is dominating the multiple sclerosis treatment market because it is the most common form of multiple sclerosis at onset and accounts for about 85% of all cases.
  • On the basis of treatment, the multiple sclerosis treatment market is segmented into symptomatic therapies, abortive therapies/treatment of acute exacerbations and preventive therapies. In 2020, preventive therapies segment is dominating the multiple sclerosis treatment market as the immune system eats away at the protective covering of nerves, and the prevention is highly sought after.
  • On the basis of drug type, the multiple sclerosis treatment market is segmented into branded and generic. In 2020, branded segment is dominating the multiple sclerosis treatment market because of large number of products which are being launched from time-to-time by several companies making it difficult for generics to take over the market.
  • On the basis of route of administration, the multiple sclerosis treatment market is segmented into oral and parenteral. In 2020, oral segment is dominating the multiple sclerosis treatment market because of the increased bioavailability of the oral drug at the target site.
  • On the basis of end user, the multiple sclerosis treatment market is segmented into hospital, specialty centers, homecare and others. In 2020, hospital segment is dominating the multiple sclerosis treatment market because of the large number of patients visiting the hospitals due to the presence of skilled professionals and advanced technology for the diagnosis.
  • On the basis of distribution channel, the multiple sclerosis treatment market is segmented into direct tender and retail sales. In 2020, retail sales segment is dominating the multiple sclerosis treatment market because retail sales focus heavily on the costs associated with overhead and they provide instant gratification.

Europe Multiple Sclerosis Treatment Market Country Level Analysis

Europe multiple sclerosis treatment market is analysed and market size information is provided by country, disease type, treatment, drug type, route of administration, end user and distribution channel as referenced above.

The countries covered in the Europe multiple sclerosis treatment market report are the U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland and rest of Europe.

Europe is expected to grow with the second highest growth rate in the forecast period of 2020 to 2027 due to introduction of brand new treatment options for multiple sclerosis in the region. Germany is dominating the Europe multiple sclerosis treatment market with the increasing research and development for drug development in the region. France is dominating the multiple sclerosis treatment market due to increased awareness of people regarding multiple sclerosis and its treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Awareness for Multiple Sclerosis Treatment is creating New Opportunities for Players in the Multiple Sclerosis Treatment Market

Multiple sclerosis treatment market also provides you with detailed market analysis for every country growth in particular industry with multiple sclerosis treatment sales, impact of advancement in the multiple sclerosis treatment and changes in regulatory scenarios with their support for the multiple sclerosis treatment market. The data is available for historic period 2010 to 2018

Competitive Landscape and Multiple Sclerosis Treatment Market Share Analysis

Multiple sclerosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to multiple sclerosis treatment market.

The major players covered in the Europe multiple sclerosis treatment market report are Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), F. Hoffmann-La Roche Ltd, Merck KGaA, Mallinckrodt, Pfizer Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Acorda Therapeutics, Inc., Novartis AG, Biogen, CELGENE CORPORATION (a subsidiary of Bristol-Myers Squibb Company), Lannett, Bayer AG, Amneal Pharmaceuticals LLC among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the multiple sclerosis treatment market.

For instance,

  • In August 2020, Novartis AG received the U.S. FDA approval for its drug Kesimpta (ofatumumab) for the indication of treatment of relapsing multiple sclerosis. The new drug approval received by the company for its only self-administered targeted B-cell therapy for patients having relapsing MS has increased its demand in the market leading to increased revenue in future.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the multiple sclerosis treatment market which also provides the benefit for organisation to improve their offering for multiple sclerosis treatment.

Customization Available: Europe Multiple Sclerosis Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE

TABLE 3 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 1 EUROPE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 2 EUROPE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 3 EUROPE PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 EUROPE SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 6 EUROPE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 EUROPE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 8 EUROPE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 9 EUROPE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 EUROPE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 11 EUROPE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 EUROPE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 13 EUROPE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 EUROPE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 15 EUROPE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 EUROPE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 EUROPE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 EUROPE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 EUROPE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 20 EUROPE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 21 EUROPE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 23 EUROPE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 EUROPE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 25 EUROPE GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 26 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 27 EUROPE ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 28 EUROPE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 29 EUROPE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 30 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 31 EUROPE HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 EUROPE HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 33 EUROPE SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 EUROPE OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 35 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 36 EUROPE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 EUROPE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 38 EUROPE DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 40 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 41 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 42 EUROPE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 43 EUROPE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 44 EUROPE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 45 EUROPE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 46 EUROPE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 47 EUROPE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 48 EUROPE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 49 EUROPE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 50 EUROPE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 51 EUROPE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 52 EUROPE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 53 EUROPE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 54 EUROPE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 55 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 56 EUROPE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 57 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 58 EUROPE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 59 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 60 EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 61 EUROPE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 62 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 63 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 GERMANY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 GERMANY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 GERMANY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 GERMANY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 GERMANY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 GERMANY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 GERMANY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 GERMANY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 GERMANY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 GERMANY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 GERMANY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 GERMANY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 GERMANY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 78 GERMANY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 79 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 80 GERMANY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 81 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 82 GERMANY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 83 GERMANY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 84 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 85 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 86 FRANCE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 87 FRANCE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 FRANCE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 FRANCE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 90 FRANCE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 91 FRANCE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 FRANCE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 FRANCE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 FRANCE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 FRANCE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 FRANCE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 FRANCE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 FRANCE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 99 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 100 FRANCE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 101 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 102 FRANCE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 103 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 104 FRANCE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 105 FRANCE RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 106 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 107 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 U.K. PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 109 U.K. ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 110 U.K. INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 111 U.K. INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 112 U.K. GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 113 U.K. INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 114 U.K. INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 115 U.K. ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 U.K. CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 U.K. IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 118 U.K. SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 119 U.K. MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 U.K. FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 121 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 122 U.K. BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 123 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 124 U.K. PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 125 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 126 U.K. MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 127 U.K. RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 128 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 129 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 ITALY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 ITALY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 ITALY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 133 ITALY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 ITALY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 ITALY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 ITALY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 137 ITALY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 138 ITALY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 139 ITALY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 140 ITALY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 141 ITALY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 142 ITALY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 143 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 144 ITALY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 145 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 146 ITALY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 147 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 148 ITALY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 149 ITALY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 150 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 151 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 NETHERLANDS PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 NETHERLANDS ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 NETHERLANDS INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 NETHERLANDS INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 NETHERLANDS GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 NETHERLANDS INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 NETHERLANDS INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 NETHERLANDS ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 NETHERLANDS CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 NETHERLANDS IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 NETHERLANDS SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 NETHERLANDS MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 NETHERLANDS FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 165 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 166 NETHERLANDS BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 167 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 168 NETHERLANDS PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 169 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 170 NETHERLANDS MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 171 NETHERLANDS RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 172 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 173 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 174 SPAIN PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 175 SPAIN ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 176 SPAIN INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 177 SPAIN INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 178 SPAIN GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 179 SPAIN INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 180 SPAIN INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 181 SPAIN ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 182 SPAIN CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 183 SPAIN IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 184 SPAIN SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 185 SPAIN MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 186 SPAIN FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 187 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 188 SPAIN BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 189 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 190 SPAIN PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 191 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 192 SPAIN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 193 SPAIN RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 194 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 195 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 196 RUSSIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 197 RUSSIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 198 RUSSIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 199 RUSSIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 200 RUSSIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 201 RUSSIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 202 RUSSIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 203 RUSSIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 204 RUSSIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 205 RUSSIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 206 RUSSIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 207 RUSSIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 208 RUSSIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 209 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 210 RUSSIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 211 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 212 RUSSIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 213 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 214 RUSSIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 215 RUSSIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 216 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 217 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 218 SWITZERLAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 219 SWITZERLAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 220 SWITZERLAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 221 SWITZERLAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 222 SWITZERLAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 223 SWITZERLAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 224 SWITZERLAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 225 SWITZERLAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 226 SWITZERLAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 227 SWITZERLAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 228 SWITZERLAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 229 SWITZERLAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 230 SWITZERLAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 231 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 232 SWITZERLAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 233 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 234 SWITZERLAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 235 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 236 SWITZERLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 237 SWITZERLAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 238 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 239 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 240 BELGIUM PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 241 BELGIUM ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 242 BELGIUM INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 243 BELGIUM INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 244 BELGIUM GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 245 BELGIUM INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 246 BELGIUM INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 247 BELGIUM ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 248 BELGIUM CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 249 BELGIUM IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 250 BELGIUM SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 251 BELGIUM MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 252 BELGIUM FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 253 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 254 BELGIUM BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 255 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 256 BELGIUM PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 257 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 258 BELGIUM MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 259 BELGIUM RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 260 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 261 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 262 TURKEY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 263 TURKEY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 264 TURKEY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 265 TURKEY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 266 TURKEY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 267 TURKEY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 268 TURKEY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 269 TURKEY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 270 TURKEY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 271 TURKEY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 272 TURKEY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 273 TURKEY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 274 TURKEY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 275 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 276 TURKEY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 277 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 278 TURKEY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 279 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 280 TURKEY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 281 TURKEY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 282 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 283 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 284 AUSTRIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 285 AUSTRIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 286 AUSTRIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 287 AUSTRIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 288 AUSTRIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 289 AUSTRIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 290 AUSTRIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 291 AUSTRIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 292 AUSTRIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 293 AUSTRIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 294 AUSTRIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 295 AUSTRIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 296 AUSTRIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 297 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 298 AUSTRIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 299 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 300 AUSTRIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 301 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 302 AUSTRIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 303 AUSTRIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 304 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 305 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 306 NORWAY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 307 NORWAY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 308 NORWAY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 309 NORWAY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 310 NORWAY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 311 NORWAY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 312 NORWAY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 313 NORWAY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 314 NORWAY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 315 NORWAY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 316 NORWAY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 317 NORWAY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 318 NORWAY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 319 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 320 NORWAY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 321 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 322 NORWAY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 323 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 324 NORWAY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 325 NORWAY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 326 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 327 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 328 HUNGARY PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 329 HUNGARY ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 330 HUNGARY INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 331 HUNGARY INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 332 HUNGARY GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 333 HUNGARY INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 334 HUNGARY INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 335 HUNGARY ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 336 HUNGARY CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 337 HUNGARY IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 338 HUNGARY SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 339 HUNGARY MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 340 HUNGARY FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 341 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 342 HUNGARY BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 343 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 344 HUNGARY PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 345 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 346 HUNGARY MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 347 HUNGARY RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 348 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 349 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 350 LITHUANIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 351 LITHUANIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 352 LITHUANIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 353 LITHUANIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 354 LITHUANIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 355 LITHUANIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 356 LITHUANIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 357 LITHUANIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 358 LITHUANIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 359 LITHUANIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 360 LITHUANIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 361 LITHUANIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 362 LITHUANIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 363 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 364 LITHUANIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 365 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 366 LITHUANIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 367 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 368 LITHUANIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 369 LITHUANIA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 370 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 371 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 372 IRELAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 373 IRELAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 374 IRELAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 375 IRELAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 376 IRELAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 377 IRELAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 378 IRELAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 379 IRELAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 380 IRELAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 381 IRELAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 382 IRELAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 383 IRELAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 384 IRELAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 385 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 386 IRELAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 387 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 388 IRELAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 389 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 390 IRELAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 391 IRELAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 392 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 393 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 394 POLAND PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 395 POLAND ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 396 POLAND INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 397 POLAND INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 398 POLAND GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 399 POLAND INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 400 POLAND INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 401 POLAND ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 402 POLAND CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 403 POLAND IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 404 POLAND SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 405 POLAND MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 406 POLAND FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 407 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 408 POLAND BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE (USD MILLION)

TABLE 409 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 410 POLAND PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 411 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 412 POLAND MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 413 POLAND RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 414 REST OF EUROPE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions